Effect of Sacubitril/Valsartan on Natriuretic Peptide in Patients with Compensated Heart Failure

Not Applicable

Recruiting

• Conditions: chronic heart failure

• Registration Number: JPRN-UMIN000046574
• Lead Sponsor: ippon Medical School

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-01-08
• Last Update Posted: 17 October 2023
• Study Completion: 2023-12-31

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Not provided

Exclusion Criteria

Patients with end-stage chronic kidney disease (eGFR<30 mL/min/1.73m2) were excluded from present study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
natriuretic peptide families

Secondary Outcome Measures

Name	Time	Method
1) Serum Renin, aldosterone and AngiotensinII 2) medication 3) age, gender, presence of de novo or recurrent HF, etiology of HF, past medical history (risk factors for atherosclerosis [diabetes mellitus, hypertension, and dyslipidemia], and chronic kidney disease), vital signs (systolic blood pressure [SBP] and heart rate), laboratory data (blood urea nitrogen, creatinine, total bilirubin, sodium, potassium, hemoglobin and C-reactive protein [CRP]) 4) left ventricular ejection fraction (LVEF) on echocardiography 5) Prognosis (mortality and heart failure event within 1 year)